WebMar 13, 2024 · HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. WebMar 17, 2024 · BOSTON, March 17, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. HLVX, a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...
HilleVax Reports Full Year 2024 Financial Results and Highlights …
WebNovartis Vaccines. Nov 2009 - Oct 20112 years. On international assignment in Germany, managed a department of over 50 people which incorporated Sterility Assurance oversight for the site into the ... WebLife At Hillevax; Investors and Media. Overview; News & Events; Stock Information; Corporate Governance; Financial Information; IR Resources; Contact Us Rob Hershberg, M.D., Ph.D., is President, Chief Executive Officer and chairman of … Norovirus. Norovirus is the most common cause of viral acute gastroenteritis (AGE) … HilleVax has no obligation to provide any form of compensation in return for any … BOSTON, March 17, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: … Get in touch to find out more about HilleVax. 75 State St., Suite 100, Boston, … BOSTON, March 17, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: … Stock Information - Hillevax - Advancing a Vaccine to Protect Against Norovirus Corporate Governance - Hillevax - Advancing a Vaccine to Protect Against … Financial Information - Hillevax - Advancing a Vaccine to Protect Against Norovirus HilleVax priced its initial public offering on April 29, 2024. What is HilleVax’s fiscal … tsa offers flights
Senior Scientist Salary at Hillevax Inc Salary.com
WebShe is currently the Head of Clinical Serology at HilleVax, Inc, a biopharmaceutical company focused on the development and commercialization of a vaccine candidate for Norovirus. Shannon has ... WebJ.P. Morgan Sticks to Its Buy Rating for HilleVax, Inc (HLVX) 03/31/23-7:16AM EST TipRanks HilleVax GAAP EPS of -$0.56 03/20/23-5:31AM EST Seeking Alpha WebBOSTON, March 17, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel … tsa office fort lauderdale